Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
WINDTREE THERAPEUTICS INC /DE/ incurred senior notes of $1.5 million with the buyers named therein at 10.0% per annum maturing January 2, 2025.
- Instrument
- senior notes
- Principal
- $1.5 million
- Counterparty
- the buyers named therein
- Rate
- 10.0% per annum
- Maturity
- January 2, 2025
- Event
- incurrence
Exact text from the filing
the Company agreed to sell senior convertible notes in an aggregate principal amount of $1.5 million
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
WINDTREE THERAPEUTICS INC /DE/: Filed Certificate of Designation establishing Series B Preferred Stock effective April 3, 2024 (effective 2024-04-03).
- Change
- charter amendment
- Effective
- 2024-04-03
Exact text from the filing
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Pursuant to the Asset Purchase Agreement, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware on April 2, 2024 for the purpose of establishing and designating the Series B Preferred Stock. The Certificate of Designation became effective on April 3, 2024.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
WINDTREE THERAPEUTICS INC /DE/ entered into Asset Purchase Agreement with Varian Biopharmaceuticals, Inc. valued at up to $2,300,000 (effective 2024-04-02).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Varian Biopharmaceuticals, Inc.
- Value
- up to $2,300,000
- Effective
- 2024-04-02
Exact text from the filing
On April 2, 2024, Windtree Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), by and between the Company and Varian Biopharmaceuticals, Inc., a Florida corporation (“Varian”).
View on SEC.gov